[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
April 24, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going...
Borregaard ASA: EBITDA1 of NOK 442 million in the 1st quarter
April 24, 2024 01:00 ET
|
Borregaard
Borregaard’s operating revenues reached NOK 1,975 million (NOK 1,850 million)2 in the 1st quarter of 2024. EBITDA1 increased to NOK 442 million (NOK 435 million). The result in BioSolutions increased...
IMCD Spain expands its Pharmaceuticals presence with the acquisition of Cobapharma
April 24, 2024 01:00 ET
|
IMCD N.V.
ROTTERDAM, The Netherlands 24 April 2024 – IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, today announces that IMCD Spain has signed an agreement to...
Wereldhave Trading update Q1 2024
April 24, 2024 01:00 ET
|
Wereldhave N.V.
Full Service Center footfall continues to power ahead: 10% above Q1 2023Retail sales +5%, well above inflationPolarizing leasing market in the Benelux with several expanding formulas but also some...
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates
April 24, 2024 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates In-depth analysis of VIVIAD Phase 2b results is ongoing, including...
BioSenic postpones its annual general meeting of the shareholders and provides temporary non-audited financial figures for 2023
April 24, 2024 01:00 ET
|
BioSenic
PRESS RELEASE - PRIVILEGED INFORMATION In view of the restructuring plan announced on April 11, 2024, BioSenic has decided to postpone the publication of its 2023 annual report as well as its...
TGS Q1 2024 Presentation and Webcast
April 24, 2024 01:00 ET
|
TGS ASA
OSLO, Norway (24 April 2024) - TGS will release its Q1 2024 results at approximately 07:00 CEST on 8 May 2024. CEO Kristian Johansen and CFO Sven Børre Larsen will present the results at 09:00 CEST at...
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
April 24, 2024 01:00 ET
|
Ipsen Pharma
PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024. Q1 2024 Q1 2023 %...
Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards
April 24, 2024 01:00 ET
|
Pharming Group N.V.
Recognition given for achievement in commercializing Joenja® (leniolisib), a first-in-class medication brought to market 10 years after disease state, APDS, was first characterized Leiden, the...
NaaS Technology and its Parent Company, NewLink, Join the Open Invention Network Community
April 24, 2024 01:00 ET
|
Open Invention Network
New energy asset operator NaaS is reinforcing its commitment to open source by joining Open Invention Network.